Skip to main content
. 2018 Jul 20;26(8):1155–1161. doi: 10.1016/j.jsps.2018.07.003

Table 3.

Classification of the adverse drug events detected in the intensive care unit of a tertiary hospital in the Brazilian Midwest. Brazil, 2016.

Trigger Tool Non-targeted chart review p
Adverse drug events 98 122
Patients experiencing adverse drug events (%) 65 (40.12%) 73 (43,19%) 0.321a
Cumulative incidence (ADE/patient) 0.60 0.72
Incidence density rate (ADE/1000 patient-days) 61.09 64.04
Causality: Naranjo algorithm (Naranjo et al., 1981) 0.001a
 <0 points: Doubtful
 1–4 points: Possible 28 (28.57%) 12 (9.84%)
 5–8 points: Probable 63 (64.29%) 95 (77.87%)
 >9 points: Definite 7 (7.14%) 15 (12.29%)



Severity: CTCAE v4.0 (National Cancer Institute, 2010) 0.029 a
 Grade 1: Mild, asymptomatic, intervention not indicated 7 (7.14%) 17 (13.93%)
 Grade 2: Moderate, requires local or noninvasive intervention 36 (36.74%) 48 (39.34%)
 Grade 3: Severe, not immediately life-threatening, prolongs hospitalization 32 (32.65%) 45 (36.89%)
 Grade 4: Life-threatening, requires urgent intervention 23 (23.47%) 12 (9.84%)
 Grade 5: Death related to adverse event



Predictability: (Rawlins and Thompson, 1991) 0.991a
 Type A: Dosing-dependent, predictable 86 (87.76%) 107 (87.70%)
 Type B: Pharmacologically unexpected, idiosyncratic 12 (12.24%) 15 (12.30%)



Damage: NCC MERP Index for Categorizing Medication Errors (National Coordinating Council for Medication Error Reporting, 2001) 0.099a
 Category E: Temporary harm to the patient and required intervention 55 (56.12%) 62 (50.82%)
 Category F: Temporary harm to the patient and prolonged hospitalization 24 (24.49%) 46 (37.70%)
 Category G: Permanent patient harm 2 (2.04%) 3 (2.46%)
 Category H: Intervention necessary to sustain life 17 (17.35%) 11 (9.02%)
 Category I: Patient death

CTCAE: Common Terminology Criteria for Adverse Events version 4.0.

a

Pearson's chi-square test for independence.